Sort
8,912 grants matching “sars cov 2”
Severity Predictors Integrating salivary Transcriptomics and proteomics with Multi neural network Intelligence in SARS-CoV2 infection in Children (SPITS MISC)
$713,937Usha Sethuraman · Central Michigan University · R33 · FY2023 · HD
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
$713,864Jun Wang · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI
De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics
$713,861David Baker · University Of Washington · R01 · FY2022 · AI
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections
$713,845Shirit Einav · Stanford University · R01 · FY2023 · AI
Role of eosinophil cationic proteins in cardiac hypertrophy
$713,655Peter Libby · Brigham And Women'S Hospital · R01 · FY2025 · HL
Role of eosinophil cationic proteins in cardiac hypertrophy
$713,654Peter Libby · Brigham And Women'S Hospital · R01 · FY2023 · HL
Clinical Interventional Studies of HIV Reservoirs
$713,000Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Mechanisms of viral proteases in coronavirus replication and pathogenesis
$712,986Susan C. Baker · Loyola University Chicago · R01 · FY2013 · AI
Molecular Allergy
$712,865Geoffrey Mueller · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
Assessing the determinants of durable protective immunity in SARS-CoV-2 infected human subjects
$712,821Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2021 · AI
Characterizing persistent subclinical neurobehavioral effects of COVID-19 in a diverse urban population
$712,681Michael Lawrence Lipton · Albert Einstein College Of Medicine · R01 · FY2022 · NS
Marshallese: Alternate Surveillance for COVID-19 in a Unique Population
$712,557Denise A Dillard · Washington State University · R01 · FY2023 · MD
SARS-CoV-2 Studies
$712,523Douglas Bell · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
Immunogen Design for SARS-CoV-2
$712,375Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Identification, structures and ontogenies of SARS-CoV-2 antibodies
$712,375Tongqing Zhou · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Immune response to COVID-19 vaccine in HIV infected men and women
$712,337Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
$711,960Matteo Porotto · Columbia University Health Sciences · R01 · FY2024 · AI
When are in-person HIV services worth the risk of COVID-19 and other communicable illnesses? Optimizing choices when virtual services are less effective
$711,920Anna Bershteyn · New York University School Of Medicine · R01 · FY2024 · MH
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies
$711,873Rong Fan · Yale University · U01 · FY2022 · CA
Unconventional protein secretion-mediated protein quality control in health and diseases
$711,485Yihong Ye · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung
$710,591Ya-Wen Chen · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · HL
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
$710,512Matteo Porotto · Columbia University Health Sciences · R01 · FY2025 · AI
Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sex
$710,444Delisa Fairweather · Mayo Clinic Jacksonville · R01 · FY2024 · HL
EpiMoRPH: A simulation environment for generating spatially-refined intervention strategies for the control of infectious disease
$710,264Joseph Mihaljevic · Northern Arizona University · R01 · FY2024 · AI
COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder
$710,065Elaine L Hill · University Of Rochester · U01 · FY2024 · DA